Search

Your search keyword '"Barberis, Massimo"' showing total 749 results
Start Over Author "Barberis, Massimo"
749 results on '"Barberis, Massimo"'

3. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Zola, Paolo, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, Clamp, Andrew, Persic, Mojca, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Baron-Hay, Sally, Abeni, Chiara, Martin Lorente, Cristina, Cueva, Juan Fernando, Trillsch, Fabian, Heitz, Florian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tazbirkova, Andrea, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Watary, Hidemichi, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Harrison, Michelle, Wilkinson, Kate, Goh, Jeffrey, Glasgow, Amanda, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Colombo, Ilaria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lin, Hao, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Kim, Yong Man, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo, Torri, Valter, Santoni, Anna, Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Rabaglio, Manuela, Marmé, Frederic, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Tasca, Giulia, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Rulli, Eliana, Uggeri, Sara, and Barretina Ginesta, M Pilar

Published
2024
Full Text
View/download PDF

4. Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ

Author

Guerini-Rocco, Elena, Bellerba, Federica, Concardi, Alberto, Taormina, Sergio Vincenzo, Cammarata, Giulio, Fumagalli, Caterina, Guerrieri-Gonzaga, Aliana, Macis, Debora, Del Fiol Manna, Eliza, Balladore, Emanuela, Cannone, Maria, Veronesi, Paolo, Fusco, Nicola, Bonanni, Bernardo, Viale, Giuseppe, Barberis, Massimo, Gandini, Sara, and Lazzeroni, Matteo

Published
2024
Full Text
View/download PDF

7. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

Author

Boscolo Bielo, Luca, primary, Repetto, Matteo, additional, Crimini, Edoardo, additional, Belli, Carmen, additional, Setola, Elisabetta, additional, Parma, Gabriella, additional, Fusco, Nicola, additional, Barberis, Massimo, additional, Guerini Rocco, Elena, additional, Marra, Antonio, additional, Colombo, Nicoletta, additional, and Curigliano, Giuseppe, additional

Published
2024
Full Text
View/download PDF

8. CDH1 Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype

Author

Corso, Giovanni, primary, Marino, Elena, additional, Zanzottera, Cristina, additional, Oliveira, Carla, additional, Bernard, Loris, additional, Macis, Debora, additional, Figueiredo, Joana, additional, Pereira, Joana, additional, Carneiro, Patrícia, additional, Massari, Giulia, additional, Barberis, Massimo, additional, De Scalzi, Alessandra Margherita, additional, Taormina, Sergio Vincenzo, additional, Sajjadi, Elham, additional, Sangalli, Claudia, additional, Gandini, Sara, additional, D’Ecclesiis, Oriana, additional, Trovato, Cristina Maria, additional, Rotili, Anna, additional, Pesapane, Filippo, additional, Nicosia, Luca, additional, La Vecchia, Carlo, additional, Galimberti, Viviana, additional, Guerini-Rocco, Elena, additional, Bonanni, Bernardo, additional, and Veronesi, Paolo, additional

Published
2024
Full Text
View/download PDF

9. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Author

Conforti, Fabio, Zucali, Paolo Andrea, Pala, Laura, Catania, Chiara, Bagnardi, Vincenzo, Sala, Isabella, Della Vigna, Paolo, Perrino, Matteo, Zagami, Paola, Corti, Chiara, Stucchi, Sara, Barberis, Massimo, Guerini-Rocco, Elena, Di Venosa, Benedetta, De Vincenzo, Fabio, Cordua, Nadia, Santoro, Armando, Giaccone, Giuseppe, and De Pas, Tommaso Martino

Published
2022
Full Text
View/download PDF

10. Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study – a phase I/II clinical trial protocol

Author

Zerella, Maria Alessia, Zaffaroni, Mattia, Ronci, Giuseppe, Dicuonzo, Samantha, Rojas, Damaris Patricia, Morra, Anna, Fodor, Cristiana, Rondi, Elena, Vigorito, Sabrina, Botta, Francesca, Cremonesi, Marta, Garibaldi, Cristina, Penco, Silvia, Galimberti, Viviana Enrica, Intra, Mattia, Gandini, Sara, Barberis, Massimo, Renne, Giuseppe, Cattani, Federica, Veronesi, Paolo, Orecchia, Roberto, Jereczek-Fossa, Barbara Alicja, and Leonardi, Maria Cristina

Published
2022
Full Text
View/download PDF

11. miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response

Author

Cuttano, Roberto, Colangelo, Tommaso, Guarize, Juliana, Dama, Elisa, Cocomazzi, Maria Pia, Mazzarelli, Francesco, Melocchi, Valentina, Palumbo, Orazio, Marino, Elena, Belloni, Elena, Montani, Francesca, Vecchi, Manuela, Barberis, Massimo, Graziano, Paolo, Pasquier, Andrea, Sanz-Ortega, Julian, Montuenga, Luis M., Carbonelli, Cristiano, Spaggiari, Lorenzo, and Bianchi, Fabrizio

Published
2022
Full Text
View/download PDF

13. Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers.

Author

Belli, Carmen, Bielo, Luca Boscolo, Repetto, Matteo, Crimini, Edoardo, Scalia, Raimondo, Diana, Anna, Orefice, Jessica, Ascione, Liliana, Pellizzari, Gloria, Fusco, Nicola, Barberis, Massimo, Daniele, Bruno, Guerini-Rocco, Elena, and Curigliano, Giuseppe

Subjects
BILE duct tumors, RETROSPECTIVE studies, CANCER patients, DESCRIPTIVE statistics, CANCER chemotherapy, DNA repair, DRUG efficacy, MEDICAL records, ACQUISITION of data, RESEARCH, ONCOGENES, DNA damage, PROGRESSION-free survival, COMPARATIVE studies, CONFIDENCE intervals, PLATINUM, SEQUENCE analysis, OVERALL survival
Abstract

Background Platinum-based chemotherapy represents the standard first-line treatment for biliary tract cancers (BTC). Deficits in genes involved in the homologous recombination (HR) and DNA damage response (DDR) may confer higher sensitivity to platinum agents. Methods We retrospectively included patients affected by BTC from 2 Italian institutions. Inclusion criteria consist of the receipt of platinum-based chemotherapy in the metastatic setting and the availability of comprehensive genomic profiling using next-generation sequencing (NGS). Patients were included in the HRD-like group if demonstrated oncogenic or likely oncogenic alterations in HR-/DDR-genes. Clinical endpoints were compared between the HRD-like group and the non-HRD-like group. Results Seventy-four patients were included, of whom 25 (33%) in the HRD-like group and 49 (66%) in the non-HRD group. With a median follow-up of 26.04 months (interquartile-range [IQR] 9.41-29.27) in the HRD-like group and of 22.48 months (IQR 16.86-40.53) in the non-HRD group, no PFS difference emerged, with a mPFS of 5.18 months in the HRD-like group compared to 6.04 months in the non-HRD group (hazard ratio [HR], 1.017, 95% CI 0.58-1.78; P  = .95). No differences were observed in DCR (64% [95 CI 45%-83%] vs 73% [95 CI 61%-86%]; P  = .4), and CBR (45% [95% CI 28%-73%] vs 50% [95% CI, 37%-68%]; P  = .9) between the HRD-like group and non-HRD groups, respectively. Median OS did not statistically differ between the HRD-like group and non-HRD group (26.7 vs 18.0 months, respectively; HR, 0.670, 0.33 to 1.37, P  = .27). Conclusion HR-/DDR-genes, when assessed with regular tumor-only NGS panels, provide limited clinical validity to identify patients with BTC more likely to benefit from platinum-based chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.

Author

Pepe, Francesco, Guerini-Rocco, Elena, Fassan, Matteo, Fusco, Nicola, Vacirca, Davide, Ranghiero, Alberto, Venetis, Konstantinos, Rappa, Alessandra, Taormina, Sergio Vincenzo, Russo, Gianluca, Rebellato, Elena, Munari, Giada, Moreno-Manuel, Andrea, De Angelis, Carmine, Zamagni, Claudio, Valabrega, Giorgio, Malapelle, Umberto, Troncone, Giancarlo, Barberis, Massimo, and Iaccarino, Antonino

Subjects
HOMOLOGOUS recombination, OVARIAN cancer, DEEP learning, INDUCED ovulation, DOUBLE-strand DNA breaks, PILOT projects
Published
2024
Full Text
View/download PDF

15. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.

Author

Bielo, Luca Boscolo, Repetto, Matteo, Crimini, Edoardo, Belli, Carmen, Setola, Elisabetta, Parma, Gabriella, Fusco, Nicola, Barberis, Massimo, Rocco, Elena Guerini, Marra, Antonio, Colombo, Nicoletta, and Curigliano, Giuseppe

Subjects
UTERINE tumors, BRCA genes, GENOMICS, LEIOMYOSARCOMA, ENZYME inhibitors, TREATMENT effectiveness, GENES, DNA damage, GENETIC mutation, SEQUENCE analysis, DISEASE progression, HISTOLOGY
Abstract

Background Uterine leiomyosarcoma (uLMS) represents one of the most common sarcoma histotypes, demonstrating an overall dismal prognosis. Previous studies reported uLMS to carry recurrent somatic BRCA2 homozygous deletions, related to significant clinical benefits from the use of PARP inhibitors. Methods To investigate the prevalence in uLMS of genomic alterations (alt) in BRCA2 and other homologous recombination (HR) and DNA damage response (DDR) genes, cBioPortal was accessed and data were retrieved from studies including pan-sarcoma histologies. HR-/DDR-genes included BRCA1 , BRCA2 , ATM , BARD1 , BRIP1 , CHEK1 , CHEK2 , FANCA , FANCB , FANCC , FANCD2 , FANCE , FANCF , FANCG , FANCI , FANCL , FANCM , NBN , PALB2 , RAD51C , RAD51D , RAD50 , and ATR. Only oncogenic/likely oncogenic alterations were included according to OncoKB. Clinical Report and Results We reported a clinical case of a patient affected by a highly pretreated uLMS discussed at the European Institute of Oncology Molecular Tumor Board. A targeted next-generation sequencing panel demonstrated a somatic BRCA2 homozygous deletion (homDel). Upon access to Niraparib, a remarkable response of 15 months was observed before experiencing disease progression. In the genomic query, among 2393 cases, uLMS (n  = 193) displayed 9 of all 31 BRCA2 alt observed, representing the only sarcoma histotype showing an enrichment in BRCA2 alt (4.66%; q  < 0.001). All of 9 BRCA2 alt were represented by homDel, which related to a high fraction of genome altered. Conclusion uLMS displays a significant frequency of somatic BRCA2 alt homDel. Considering their dismal prognosis, further investigation is warranted to test the use of PARPi in uLMS, and particularly in the setting of BRCA1/2 alterations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer

Author

Betella, Ilaria, Fumagalli, Caterina, Rafaniello Raviele, Paola, Schivardi, Gabriella, De Vitis, Luigi Antonio, Achilarre, Maria Teresa, Aloisi, Alessia, Garbi, Annalisa, Maruccio, Matteo, Zanagnolo, Vanna, Aletti, Giovanni, Guerini-Rocco, Elena, Mariani, Andrea, Maggioni, Angelo, Barberis, Massimo, Colombo, Nicoletta, and Multinu, Francesco

Published
2022
Full Text
View/download PDF

18. BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

Author

Malapelle, Umberto, Rossi, Giulio, Pisapia, Pasquale, Barberis, Massimo, Buttitta, Fiamma, Castiglione, Francesca, Cecere, Fabiana Letizia, Grimaldi, Antonio Maria, Iaccarino, Antonino, Marchetti, Antonio, Massi, Daniela, Medicina, Daniela, Mele, Fabio, Minari, Roberta, Orlando, Elisabetta, Pagni, Fabio, Palmieri, Giuseppe, Righi, Luisella, Russo, Alessandro, Tommasi, Stefania, Vermi, William, and Troncone, Giancarlo

Published
2020
Full Text
View/download PDF

20. Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.

Author

Bielo, Luca Boscolo, Belli, Carmen, Crimini, Edoardo, Repetto, Matteo, Ascione, Liliana, Pellizzari, Gloria, Santoro, Celeste, Fuorivia, Valeria, Barberis, Massimo, Fusco, Nicola, Rocco, Elena Guerini, and Curigliano, Giuseppe

Subjects
GENOMICS, CANCER of unknown primary origin, CANCER patient medical care, TUMOR markers, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, CANCER chemotherapy, MEDICAL records, GENE expression profiling, DATA analysis software, CONFIDENCE intervals, SEQUENCE analysis
Abstract

Background Cancer of unknown primary origin (CUP) poses a significant challenge due to poor clinical outcomes and limited treatment options. As such, further definition of clinicopathological factors and genomic profile to better adapt treatment strategies is required. Methods Medical records were interrogated to retrospectively include CUP with available clinical and genomics data at the European Institute of Oncology. Next-generation sequencing (NGS) included targeted panels. Statistical analyses were conducted with R Software 4.2.2. Results A total of 44 patients were included. With a median follow-up of 39.46 months (interquartile range [IQR] 35.98-47.41 months), median PFS (mPFS) to first-line regimen was 3.98 months (95% CI 3.22-5.98), with a clinical benefit rate of 26% (95% CI 14%-49%), and disease control rate (DCR) limited to 48.28%. Most patients (26 of 31, 83.87%) received platinum-doublet chemotherapy, with no statistically significant difference between first-line treatment regimens. Median OS (mOS) was 18.8 months (95% CI 12.3-39.9), with a 12-month OS rate of 66% (95% CI 50%-85%). All patients received comprehensive genomic profiling (CGP). For 11 patients, NGS was unsuccessful due to low sample quantity and/or quality. For the remaining, TP53 (n  = 16, 48%) and KRAS (n  = 10, 30%) represented the most altered (alt) genes. No microsatellite instability was observed (0 of 28), while 6 of 28 (21.43%) tumors carried high TMB (≥10 mutation per megabase). Eight of 33 tumors (24.2%) displayed at least one actionable alteration with potential clinical benefit according to ESCAT. Only 2 of them received targeted therapy matched to genomic alterations, with a combined mPFS of 2.63 months (95% CI 1.84-not evaluable) as third-line regimens. Six patients received anti-PD1/PD-L1 therapy, showing a meaningful mPFS of 13 months (95% CI 2.04-not evaluable). Conclusion CUP exhibits poor prognosis with limited benefits from standard treatment regimens. A significant proportion of CUPs carry actionable alterations, underscoring the importance of genomic profiling to gather additional treatment opportunities. In addition, immunotherapy might represent a valuable treatment option for a subset of CUP. Finally, accurate definition of sequencing methods and platforms is crucial to overcome NGS failures. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Molecular Profiling of H-MSI/dMMR/for Endometrial Cancer Patients: "New Challenges in Diagnostic Routine Practice".

Author

Adorisio, Riccardo, Troncone, Giancarlo, Barberis, Massimo, and Pepe, Francesco

Subjects
ENDOMETRIAL cancer, INDIVIDUALIZED medicine, ENDOMETRIUM, POINT-of-care testing, MEDICAL care
Abstract

Endometrial cancer (EC) represents one of the most newly diagnosed cancers across gynecological malignancies. In particular, a plethora of risk factors (both biological and lifestyle-related) drastically impact the incidence rate of novel diagnosis accounting for 8300 cases/year. In the recent era of precision medicine EC molecular classification, integrating ESGO/ESTRO/ESP guidelines, four distinct diagnostic groups have been established including POLE-mutant (POLE-pos); High-instability MSI (H-MSI)–MMR-deficient (MMR-d); p53-abnormal (p53abn); and non-specific molecular profile (NSMP), also known as p53-wild-type EC patients on the basis of clinically relevant emerging biomarkers. In addition, molecular testing also plays a pivotal role in defining the best therapeutical option. In this scenario, the European Society for Medical Oncology (ESMO) recommended d-MMR/MSI-H status evaluation in the diagnostic workflow of Lynch syndrome or selecting EC patients that could benefit from immune checkpoint inhibitors (ICIs). Although immunohistochemistry (IHC) is considered the gold standard approach for d-MMR profiling, a series of molecular PCR-based techniques have rapidly developed to integrate H-MSI status in routine practice. Here, we technically overviewed the most relevant commercially available diagnostic assays for the determination of the H-MSI/dMMR status in EC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review

Author

De Vitis, Luigi Antonio, primary, Schivardi, Gabriella, additional, Caruso, Giuseppe, additional, Fumagalli, Caterina, additional, Vacirca, Davide, additional, Achilarre, Maria Teresa, additional, Aloisi, Alessia, additional, Garbi, Annalisa, additional, Zanagnolo, Vanna, additional, Aletti, Giovanni, additional, Guerini-Rocco, Elena, additional, Mariani, Andrea, additional, Maggioni, Angelo, additional, Barberis, Massimo, additional, Bogani, Giorgio, additional, Colombo, Nicoletta, additional, Multinu, Francesco, additional, and Betella, Ilaria, additional

Published
2023
Full Text
View/download PDF

26. 1541 Stability of the gut microbiota during anti-pd1 immunotherapy defines complete response in melanoma patients

Author

Macandog, Angeli DG, primary, Catozzi, Carlotta, additional, Capone, Mariaelena, additional, Nabinejad, Amir, additional, Madonna, Gabriele, additional, Barberis, Massimo, additional, Ferrucci, Pier, additional, Segata, Nicola, additional, Buonaguro, Luigi, additional, Cocorocchio, Emilia, additional, Ascierto, Paolo A, additional, Manzo, Teresa, additional, and Nezi, Luigi, additional

Published
2023
Full Text
View/download PDF

27. Author Correction: A role for the immune system in advanced laryngeal cancer

Author

Tagliabue, Marta, Maffini, Fausto, Fumagalli, Caterina, Gandini, Sara, Lepanto, Daniela, Corso, Federica, Cacciola, Salvatore, Ranghiero, Alberto, Rappa, Alessandra, Vacirca, Davide, Cossu Rocca, Maria, Alterio, Daniela, Guerini Rocco, Elena, Cattaneo, Augusto, Chu, Francesco, Zorzi, Stefano, Curigliano, Giuseppe, Chiocca, Susanna, Barberis, Massimo, Viale, Giuseppe, and Ansarin, Mohssen

Published
2021
Full Text
View/download PDF

29. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

Author

Gori, Stefania, Barberis, Massimo, Bella, Maria Angela, Buttitta, Fiamma, Capoluongo, Ettore, Carrera, Paola, Colombo, Nicoletta, Cortesi, Laura, Genuardi, Maurizio, Gion, Massimo, Guarneri, Valentina, Incorvaia, Lorena, La Verde, Nicla, Lorusso, Domenica, Marchetti, Antonio, Marchetti, Paolo, Normanno, Nicola, Pasini, Barbara, Pensabene, Matilde, Pignata, Sandro, Radice, Paolo, Ricevuto, Enrico, Sapino, Anna, Tagliaferri, Pierosandro, Tassone, Pierfrancesco, Trevisiol, Chiara, Truini, Mauro, Varesco, Liliana, and Russo, Antonio

Published
2019
Full Text
View/download PDF

30. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.

Author

De Vitis, Luigi Antonio, Schivardi, Gabriella, Caruso, Giuseppe, Fumagalli, Caterina, Vacirca, Davide, Achilarre, Maria Teresa, Aloisi, Alessia, Garbi, Annalisa, Zanagnolo, Vanna, Aletti, Giovanni, Guerini-Rocco, Elena, Mariani, Andrea, Maggioni, Angelo, Barberis, Massimo, Bogani, Giorgio, Colombo, Nicoletta, Multinu, Francesco, and Betella, Ilaria

Published
2024
Full Text
View/download PDF

31. Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.

Author

Crimini, Edoardo, Tini, Giulia, Tarantino, Paolo, Ascione, Liliana, Repetto, Matteo, Beria, Paolo, Ranghiero, Alberto, Marra, Antonio, Belli, Carmen, Criscitiello, Carmen, Esposito, Angela, Rocco, Elena Guerini, Barberis, Massimo C P, Mazzarella, Luca, and Curigliano, Giuseppe

Subjects
HEALTH services accessibility, CLINICAL trials, POPULATION geography, RETROSPECTIVE studies, INDIVIDUALIZED medicine, NATIONAL health services, CANCER patients, GENOMES, GENOMICS, GENES, TUMORS, CANCER patient medical care
Abstract

Background Molecular-driven oncology allows oncologists to identify treatments that match a cancer's genomic profile. Clinical trials are promoted as an effective modality to deliver a molecularly matched treatment. We explore the role of geographical accessibility in Italy, and its impact on patient access to clinical trials. Material and Methods We retrospectively reviewed molecular data from a single-institutional case series of patients receiving next-generation sequencing testing between March 2019 and July 2020. Actionable alterations were defined as the ones with at least one matched treatment on Clinicaltrials.gov at the time of genomic report signature. We then calculated the hypothetical distance to travel to reach the nearest assigned clinical trial. Results We identified 159 patients eligible for analysis. One hundred and one could be potentially assigned to a clinical trial in Italy, and the median distance that patients needed to travel to reach the closest location with a suitable clinical trial was 76 km (interquartile range = 127.46 km). Geographical distribution of clinical trials in Italy found to be heterogeneous, with Milan and Naples being the areas with a higher concentration. We then found that the probability of having a clinical trial close to a patient's hometown increased over time, according to registered studies between 2015 and 2020. Conclusions The median distance to be travelled to the nearest trial was generally acceptable for patients, and trials availability is increasing. Nevertheless, many areas are still lacking trials, so efforts are required to increase and homogenize the possibilities to be enrolled in clinical trials for Italian patients with cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients

Author

Rinaldi, Lisa, primary, Guerini Rocco, Elena, additional, Spitaleri, Gianluca, additional, Raimondi, Sara, additional, Attili, Ilaria, additional, Ranghiero, Alberto, additional, Cammarata, Giulio, additional, Minotti, Marta, additional, Lo Presti, Giuliana, additional, De Piano, Francesca, additional, Bellerba, Federica, additional, Funicelli, Gianluigi, additional, Volpe, Stefania, additional, Mora, Serena, additional, Fodor, Cristiana, additional, Rampinelli, Cristiano, additional, Barberis, Massimo, additional, De Marinis, Filippo, additional, Jereczek-Fossa, Barbara Alicja, additional, Orecchia, Roberto, additional, Rizzo, Stefania, additional, and Botta, Francesca, additional

Published
2023
Full Text
View/download PDF

33. Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience

Author

Crimini, Edoardo, primary, Tini, Giulia, additional, Tarantino, Paolo, additional, Ascione, Liliana, additional, Repetto, Matteo, additional, Beria, Paolo, additional, Ranghiero, Alberto, additional, Marra, Antonio, additional, Belli, Carmen, additional, Criscitiello, Carmen, additional, Esposito, Angela, additional, Guerini Rocco, Elena, additional, Barberis, Massimo C P, additional, Mazzarella, Luca, additional, and Curigliano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

34. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing

Author

Ranghiero, Alberto, primary, Frascarelli, Chiara, additional, Cursano, Giulia, additional, Pescia, Carlo, additional, Ivanova, Mariia, additional, Vacirca, Davide, additional, Rappa, Alessandra, additional, Taormina, Sergio Vincenzo, additional, Barberis, Massimo, additional, Fusco, Nicola, additional, Rocco, Elena Guerini, additional, and Venetis, Konstantinos, additional

Published
2023
Full Text
View/download PDF

36. A role for the immune system in advanced laryngeal cancer

Author

Tagliabue, Marta, Maffini, Fausto, Fumagalli, Caterina, Gandini, Sara, Lepanto, Daniela, Corso, Federica, Cacciola, Salvatore, Ranghiero, Alberto, Rappa, Alessandra, Vacirca, Davide, Cossu Rocca, Maria, Alterio, Daniela, Guerini Rocco, Elena, Cattaneo, Augusto, Chu, Francesco, Zorzi, Stefano, Curigliano, Giuseppe, Chiocca, Susanna, Barberis, Massimo, Viale, Giuseppe, and Ansarin, Mohssen

Published
2020
Full Text
View/download PDF

38. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

Author

Marchetti, Antonio, Barberis, Massimo, Franco, Renato, De Luca, Graziano, Pace, Maria Vittoria, Staibano, Stefania, Volante, Marco, Buttitta, Fiamma, Guerini-Rocco, Elena, Righi, Luisella, D’antuono, Tommaso, Scagliotti, Giorgio V., Pinto, Carmine, De Rosa, Gaetano, and Papotti, Mauro

Published
2017
Full Text
View/download PDF

39. Hereditary Gastric Cancer: Single-Gene or Multigene Panel Testing? A Mono-Institutional Experience

Author

Calvello, Mariarosaria, primary, Marabelli, Monica, additional, Gandini, Sara, additional, Marino, Elena, additional, Bernard, Loris, additional, Dal Molin, Matteo, additional, Di Cola, Giulia, additional, Zanzottera, Cristina, additional, Corso, Giovanni, additional, Fazio, Nicola, additional, Gervaso, Lorenzo, additional, Fumagalli Romario, Uberto, additional, Barberis, Massimo, additional, Guerrieri-Gonzaga, Aliana, additional, Bertario, Lucio, additional, Serrano, Davide, additional, and Bonanni, Bernardo, additional

Published
2023
Full Text
View/download PDF

40. In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study

Author

Pepe, Francesco, primary, Guerini-Rocco, Elena, additional, Fassan, Matteo, additional, Fusco, Nicola, additional, Vacirca, Davide, additional, Ranghiero, Alberto, additional, Venetis, Konstantinos, additional, Rappa, Alessandra, additional, Taormina, Sergio Vincenzo, additional, Russo, Gianluca, additional, Rebellato, Elena, additional, Munari, Giada, additional, Moreno-Manuel, Andrea, additional, De Angelis, Carmine, additional, Zamagni, Claudio, additional, Valabrega, Giorgio, additional, Malapelle, Umberto, additional, Troncone, Giancarlo, additional, Barberis, Massimo, additional, and Iaccarino, Antonino, additional

Published
2023
Full Text
View/download PDF

41. Data from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

Author

Bossi, Daniela, primary, Cicalese, Angelo, primary, Dellino, Gaetano I., primary, Luzi, Lucilla, primary, Riva, Laura, primary, D'Alesio, Carolina, primary, Diaferia, Giuseppe R., primary, Carugo, Alessandro, primary, Cavallaro, Elena, primary, Piccioni, Rossana, primary, Barberis, Massimo, primary, Mazzarol, Giovanni, primary, Testori, Alessandro, primary, Punzi, Simona, primary, Pallavicini, Isabella, primary, Tosti, Giulio, primary, Giacó, Luciano, primary, Melloni, Giorgio, primary, Heffernan, Timothy P., primary, Natoli, Gioacchino, primary, Draetta, Giulio F., primary, Minucci, Saverio, primary, Pelicci, PierGiuseppe, primary, and Lanfrancone, Luisa, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables S1 - S5 from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

Author

Bossi, Daniela, primary, Cicalese, Angelo, primary, Dellino, Gaetano I., primary, Luzi, Lucilla, primary, Riva, Laura, primary, D'Alesio, Carolina, primary, Diaferia, Giuseppe R., primary, Carugo, Alessandro, primary, Cavallaro, Elena, primary, Piccioni, Rossana, primary, Barberis, Massimo, primary, Mazzarol, Giovanni, primary, Testori, Alessandro, primary, Punzi, Simona, primary, Pallavicini, Isabella, primary, Tosti, Giulio, primary, Giacó, Luciano, primary, Melloni, Giorgio, primary, Heffernan, Timothy P., primary, Natoli, Gioacchino, primary, Draetta, Giulio F., primary, Minucci, Saverio, primary, Pelicci, PierGiuseppe, primary, and Lanfrancone, Luisa, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods, Figure Legends from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

Author

Bossi, Daniela, primary, Cicalese, Angelo, primary, Dellino, Gaetano I., primary, Luzi, Lucilla, primary, Riva, Laura, primary, D'Alesio, Carolina, primary, Diaferia, Giuseppe R., primary, Carugo, Alessandro, primary, Cavallaro, Elena, primary, Piccioni, Rossana, primary, Barberis, Massimo, primary, Mazzarol, Giovanni, primary, Testori, Alessandro, primary, Punzi, Simona, primary, Pallavicini, Isabella, primary, Tosti, Giulio, primary, Giacó, Luciano, primary, Melloni, Giorgio, primary, Heffernan, Timothy P., primary, Natoli, Gioacchino, primary, Draetta, Giulio F., primary, Minucci, Saverio, primary, Pelicci, PierGiuseppe, primary, and Lanfrancone, Luisa, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures S1 - S8 from In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype

Author

Bossi, Daniela, primary, Cicalese, Angelo, primary, Dellino, Gaetano I., primary, Luzi, Lucilla, primary, Riva, Laura, primary, D'Alesio, Carolina, primary, Diaferia, Giuseppe R., primary, Carugo, Alessandro, primary, Cavallaro, Elena, primary, Piccioni, Rossana, primary, Barberis, Massimo, primary, Mazzarol, Giovanni, primary, Testori, Alessandro, primary, Punzi, Simona, primary, Pallavicini, Isabella, primary, Tosti, Giulio, primary, Giacó, Luciano, primary, Melloni, Giorgio, primary, Heffernan, Timothy P., primary, Natoli, Gioacchino, primary, Draetta, Giulio F., primary, Minucci, Saverio, primary, Pelicci, PierGiuseppe, primary, and Lanfrancone, Luisa, primary

Published
2023
Full Text
View/download PDF

48. Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples

Author

Guerini-Rocco, Elena, Passaro, Antonio, Casadio, Chiara, De Luca, Valeria Midolo, Guarize, Juliana, de Marinis, Filippo, Vacirca, Davide, and Barberis, Massimo

Subjects
Chemotherapy -- Genetic aspects -- Research, DNA sequencing -- Usage -- Research, Non-small cell lung cancer -- Genetic aspects -- Drug therapy -- Research, Health
Abstract

Context.--Molecular testing is essential for the diagnostic workup of patients with advanced non-small cell lung cancers. Cytology specimens from minimally invasive procedures, such as endobronchial ultrasound-guided transbronchial needle aspiration, are often the only available samples for these patients. The implementation of molecular diagnostic testing, and in particular next-generation sequencing-based testing, on these cytologic specimens is currently an evolving field for lung cytopathology. The application of these molecular analyses on tyrosine kinase inhibitor-resistant non-small cell lung cancers raises unique technical, biologic, and clinical challenges. Objective.--To provide an overview of the implementation of next-generation sequencing analysis on endobronchial ultrasound-guided transbronchial needle aspiration samples to detect the molecular aberrations underneath the phenomenon of acquired resistance in patients with non-small cell lung cancers progressing while on the EGFR/ALK tyrosine kinase inhibitor treatment. Data Sources.--Peer-reviewed original articles, review articles, and published guidelines and expert opinion reports were reviewed, together with our single-center experience. Conclusions.--Next-generation sequencing analyses and the endobronchial ultrasound-guided transbronchial needle aspiration procedure may represent a valuable strategy to address the unique requirements of molecular testing on tyrosine kinase inhibitor-resistant non-small cell lung cancers. doi: 10.5858/arpa.2017-0158-RA, The identification of key oncogenic events in tumor cells has allowed for the development of specific targeted therapies that have revolutionized the treatment and prognosis of patients with several types [...]

Published
2018
Full Text
View/download PDF

49. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

Author

Alvarez, Mariano J., Subramaniam, Prem S., Tang, Laura H., Grunn, Adina, Aburi, Mahalaxmi, Rieckhof, Gabrielle, Komissarova, Elena V., Hagan, Elizabeth A., Bodei, Lisa, Clemons, Paul A., Dela Cruz, Filemon S., Dhall, Deepti, Diolaiti, Daniel, Fraker, Douglas A., Ghavami, Afshin, Kaemmerer, Daniel, Karan, Charles, Kidd, Mark, Kim, Kyoung M., Kim, Hee C., Kunju, Lakshmi P., Langel, Ülo, Li, Zhong, Lee, Jeeyun, Li, Hai, LiVolsi, Virginia, Pfragner, Roswitha, Rainey, Allison R., Realubit, Ronald B., Remotti, Helen, Regberg, Jakob, Roses, Robert, Rustgi, Anil, Sepulveda, Antonia R., Serra, Stefano, Shi, Chanjuan, Yuan, Xiaopu, Barberis, Massimo, Bergamaschi, Roberto, Chinnaiyan, Arul M., Detre, Tony, Ezzat, Shereen, Frilling, Andrea, Hommann, Merten, Jaeger, Dirk, Kim, Michelle K., Knudsen, Beatrice S., Kung, Andrew L., Leahy, Emer, Metz, David C., Milsom, Jeffrey W., Park, Young S., Reidy-Lagunes, Diane, Schreiber, Stuart, Washington, Kay, Wiedenmann, Bertram, Modlin, Irvin, and Califano, Andrea

Published
2018
Full Text
View/download PDF

50. Figure S2 from Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial

Author

Guerini-Rocco, Elena, primary, Gray, Kathryn P., primary, Fumagalli, Caterina, primary, Reforgiato, Marta Rita, primary, Leone, Isabella, primary, Rafaniello Raviele, Paola, primary, Munzone, Elisabetta, primary, Kammler, Roswitha, primary, Neven, Patrick, primary, Hitre, Erika, primary, Jerusalem, Guy, primary, Simoncini, Edda, primary, Gombos, Andrea, primary, Deleu, Ines, primary, Karlsson, Per, primary, Aebi, Stefan, primary, Chirgwin, Jacquie, primary, Di Lauro, Vincenzo, primary, Thompson, Alastair, primary, Graas, Marie-Pascale, primary, Barber, Matthew, primary, Fontaine, Christel, primary, Loibl, Sibylle, primary, Gavilá, Joaquín, primary, Kuroi, Katsumasa, primary, Müller, Bettina, primary, O’Reilly, Seamus, primary, Di Leo, Angelo, primary, Goldhirsch, Aron, primary, Viale, Giuseppe, primary, Barberis, Massimo, primary, Regan, Meredith M., primary, and Colleoni, Marco, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results